Moreover, the clinical efficacy of most regimens has not yet been analyzed for KRAS-mutant NSCLC with LKB1 or KEAP1 inactivation, which is associated with the poorest prognosis (29, 102). Here, KRAS is linked to non-small cell lung carcinoma.